NEUROCRINE BIOSCIENCES INC Debt Securities, Available-for-sale, Unrealized Loss Position
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $139.60 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-07-31
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $139.60M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $1.58B.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $335.10M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $349.80M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2026-06-30 | $139.60M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $1.58B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $335.10M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $349.80M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $401.80M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $317.30M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $458.70M 10-Q · filed 2025-10-28 | |
| 2021-06-30 | $245.50M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $429.70M 10-Q · filed 2020-05-06 | |
| 2019-09-30 | $185.00M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $169.72M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $279.96M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $234.12M 10-K · filed 2020-02-07 | $577.37M 10-K · filed 2019-02-08 |
| 2017-12-31 | $577.37M 10-K · filed 2020-02-07 | $495.82M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |